外显子
表皮生长因子受体
医学
突变
肺癌
插入
肿瘤科
酪氨酸激酶
癌症研究
内科学
癌症
生物
基因
受体
遗传学
作者
Ning Zhu,Caixia Dong,Shanshan Weng,Ying Yuan,Ying Yuan
出处
期刊:JCPSP. Journal of the College of Physicians & Surgeons Pakistan
[College of Physicians and Surgeons Pakistan]
日期:2019-12-01
卷期号:: S126-S128
被引量:1
标识
DOI:10.29271/jcpsp.2019.12.s126
摘要
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard therapy for patients with advanced non-small-cell lung cancer (NSCLC) harbouring common EGFR mutations. However, about 10% of EGFR mutations are uncommon mutations and their response to EGFR-TKIs remains unclear. The present case reports a 75-year, female patient with advanced NSCLC, presenting with a new subtype of EGFR exon 19 insertion mutation (IPVAIL insertion), who showed obvious symptom improvement after EGFR-TKIs treatment but a relatively short time of progression-free survival (PFS) and succumbed to tumor 133 days (4.4 months) after diagnosis. In conclusion, patients harbouring new subtype of EGFR exon 19 insertion mutations, IPVAIL insertion may have a poor prognosis. Further experiences are required to characterise these uncommon mutations.
科研通智能强力驱动
Strongly Powered by AbleSci AI